Twist Bioscience Corporation (TWST) Stock Forecast: Should Investors Consider After 5.8% Rise?

If you’re on the hunt for stocks to watch today, Twist Bioscience Corporation (NASDAQ:TWST) is a stock to give close attention to. The company shares are trading 5.8% or 1.36 points up from last closing price of $23.44, reaching $24.8 at last check. The TWST share price has risen in 1 of the last 5 days and is up 9.33% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 27,146 shares, and in total 211146 shares valued at $5.236 million were seen changing hands compared with 184000 shares valued at $4.313 million recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the TWST stock.

Twist Bioscience Corporation (TWST) shares have notched a 3-month gain of about 9.33%, but has still advanced 1.52% year to date. By comparison, the stock sank 0% over the past 12 months, while it jumped 1.69% over the 1 month. The company’s market cap is around $733.91M, with its short interest ratio standing at 2.22%.

In the current trading session for TWST, the stock witnessed two major price actions, it rose to a high of $24.92 and was down as much as $23.32 at one point. The high recorded is very low when compared to their 52-week high which is $12.38. The 52-week high is now at -28.12 distance from current price. Their recent low of $34.46 represents a 100.08% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for TWST is $29.5, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Twist Bioscience Corporation earned $-3.52 per share in the trailing 12 months and has a P/E ratio of -7.05. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 20.25 and lower compared to the sector’s average of 20.87. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. TWST also has P/S multiple of 19.41. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 8.06x.

The company recorded an interesting insider purchase transaction by the Director on Nov 02, 2018. A Securities and Exchanges Commission filings show that Keith Crandell bought a total of 75,000 TWST shares that day for a sum of around $1,050,000. Twist Bioscience Corporation (TWST) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded no shares in the business, which makes up 0% of 12,141,907 shares that were traded over a year. In the past 12 months, insiders have purchased 12,141,907 shares while the seller parted with shares.

TWST‘s last price was up 4.75% as compared to the average trading price of 50 days recorded at $23.68 while enlarging the period to 200 trading days, the average closing price was $26.13. At present, there are 31.31 million in the total number of common shares owned by the public and among those 25.87 million shares have been available to trade. The percentage of shares being held by the company management was 21.09% while institutions stake was 29.9%. The company has generated positive returns on equity over the last 12 months (264.4%). It managed to keep its gross profit margin at -0.6% over the past 12 months.

When assessing the full upside of the TWST stock, there is another set of technicals that should be looked into and considered. Its -2.2% decline from moving average of $25.36 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Twist Bioscience Corporation — 3 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $26.325 on shares of Twist Bioscience Corporation (NASDAQ:TWST), which corresponds to 6.36% upside potential than its current market price of $24.8 and implies potential despite the recent advance in the price. However, their current target price has climbed from $25.99 a month ago and is up handily from the consensus target of $25.99 a quarter ago.

Let’s briefly check the hedge fund interest towards TWST stock. Schonfeld Strategic Advisors LLC trimmed position in the company after it dumped -55.3% or 166,443 shares of its common stock. The hedge fund now owns 74,400 shares worth $1,845,120, SEC documents show. Morgan Stanley shored up assets in the stock as 753.83 shares have been purchased, increasing its stake by 128.7% to 1,724 shares which are currently valued at $42,755. In addition, Charles Schwab Investment Management Inc. recently reported that it now owns 31,356 shares making a total of $777,629 based on the recent price. This refelects a change of 12.4% in their ownership.